IP Library › Granted Patent US 12,194,089
Granted Patent B2
US 12,194,089 · App. 17/276,788 · Granted Jan 14, 2025

Coronavirus vaccine

Inventors: Susanne Rauch (Tübingen, DE); Hans Wolfgang Große (Tübingen, DE); Benjamin Petsch (Tübingen, DE)
Assignee: CureVac SE
A61K39/215A61K9/0019A61K47/26A61P31/14A61P37/04A61K2039/53A61K2039/6018A61K2039/6093A61K2039/70
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,194,089
App. No.
17/276,788
Granted
Jan 14, 2025
Kind
B2
Abstract

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-COV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

Claims (61)

1. A composition comprising a mRNA comprising:

(a) at least one coding sequence encoding a SARS-COV-2 spike protein(S) comprising an amino acid sequence at least 90% identical to SEQ ID NO: 10 that is a pre-fusion stabilized spike protein (S_stab) comprising K986P and V987P stabilizing substitutions and further comprising E484K and D614G amino acid substitutions relative to SEQ ID NO: 10;

(b) at least one heterologous untranslated region (UTR); and

(c) at least one pharmaceutically acceptable carrier,

wherein the mRNA is complexed or associated with a lipid nanoparticle (LNP).

2. The composition of claim 1 , wherein the mRNA comprises at least one poly(A) sequence comprising 30 to 200 adenosine nucleotides and a 5′-cap structure.

3. The composition of claim 2 , wherein the at least one coding sequence of the mRNA has a G/C content of at least 50%.

4. The composition of claim 3 , wherein the mRNA comprises an RNA sequence at least 80% identical to SEQ ID NO: 23092.

5. The composition of claim 3 , wherein the at least one heterologous untranslated region is selected from at least one heterologous 5′-UTR and at least one heterologous 3′-UTR.

6. The composition of claim 3 , wherein the spike protein comprises at least three of the following amino acid substitutions relative to SEQ ID NO: 10: L18F, D80A, D215G, delL242, delA243, delL244, R246I, K417N, N501Y, and/or A701V.

7. The composition of claim 6 , wherein the spike protein comprises the following amino acid substitutions relative to SEQ ID NO: 10: L18F, D80A, D215G, delL242, delA243, delL244, R246I, K417N, E484K, N501Y, D614G and A701V.

8. The composition of claim 3 , wherein the composition comprises at least two different mRNA encoding at least two different SARS-COV-2 spike proteins.

9. The composition of claim 8 , wherein the at least two different SARS-COV-2 spike proteins are each at least 95% identical to SEQ ID NO: 10 and comprise the K986P and V987P stabilizing substitutions.

10. The composition of claim 3 , wherein the mRNA comprises a nucleotide analog.

11. The composition of claim 10 , wherein the mRNA comprises a 1-methylpseudouridine substitution.

12. The composition of claim 11 , wherein 100% of the uracil positions in the coding sequence are replaced with 1-methylpseudouridine.

13. The composition of claim 3 , wherein the mRNA is a purified mRNA that has been purified by RP-HPLC and/or TFF.

14. The composition of claim 13 , wherein the mRNA is a purified mRNA that has been purified by RP-HPLC and/or TFF and comprises about 5%, 10%, or 20% less double stranded RNA side products as an RNA that has not been purified with RP-HPLC and/or TFF.

15. A method of stimulating an immune response to a coronavirus spike protein in a subject comprising administering to the subject an effective amount of a composition according to claim 3 .

16. The method of claim 15 , wherein the administering to the subject is by intramuscular injection.

17. A composition comprising a purified RNA comprising:

(i) a 5′ cap structure;

(ii) a 5′ untranslated region (UTR);

(iii) a coding sequence encoding a SARS-COV-2 spike protein(S) comprising an amino acid sequence at least 90% identical to SEQ ID NO: 10 that is a pre-fusion stabilized spike protein (S_stab) comprising K986P and V987P stabilizing substitutions and further comprising E484K and D614G amino acid substitutions relative to SEQ ID NO: 10; and

(iv) a heterologous 3′ UTR comprising at least one poly(A) sequence having 30 to 200 consecutive adenosine nucleotides,

wherein the RNA is complexed or associated with a lipid nanoparticle (LNP) and is formulated in a pharmaceutically acceptable carrier and wherein said purified RNA optionally comprise a 1-methylpseudouridine or a pseudouridine nucleotide substitution at one or more uracil position(s).

18. The composition of claim 17 , wherein the at least one coding sequence of the RNA has a G/C content of at least 50%.

19. The composition of claim 18 , wherein 100% of the uracil positions in the RNA are replaced with 1-methylpseudouridine.

20. The composition of claim 17 , wherein the purified RNA is a replicon RNA.

21. The composition of claim 20 , wherein the replicon RNA encodes replicase elements derived from an alphavirus.

22. The composition of claim 21 , wherein the replicon RNA encodes replicase elements derived from VEE.

23. The composition of claim 21 , wherein the replicon RNA does not comprise a 1-methylpseudouridine or a pseudouridine nucleotide substitution.

24. The composition of claim 19 , wherein the purified RNA is a mRNA.

25. The composition of claim 24 , wherein the coding sequence is at least 95% identical to the RNA sequence of SEQ ID NO: 146.

26. The composition of claim 25 , wherein the coding sequence is at least 97% identical to the RNA sequence of SEQ ID NO: 146.

27. The composition of claim 26 , wherein the coding sequence is at least 98% identical to the RNA sequence of SEQ ID NO: 146.

28. The composition of claim 18 , wherein the RNA has been purified by a method comprising tangential flow filtration (TFF).

29. The composition of claim 18 , wherein the composition further comprises a second purified RNA encoding a second viral antigen.

30. The composition of claim 18 , wherein the 5′ cap structure is a cap1.

31. The composition of claim 18 , wherein the RNA comprises a terminal poly(A) sequence of 30 to 200 consecutive adenosine nucleotides.

32. The composition of claim 18 , wherein the pre-fusion stabilized spike protein comprises K417N, E484K, N501Y, and D614G amino acid substitutions relative to SEQ ID NO: 10.

33. A method of stimulating an immune response to a SARS-COV-2 spike protein in a subject comprising administering to the subject an effective amount of a pharmaceutical composition of claim 18 by intramuscular injection.

34. The method of claim 33 , wherein the subject is a human subject.

35. The method of claim 34 , wherein the composition comprises about 1 μg to about 200 μg of the purified RNA.

36. The method of claim 35 , wherein the composition comprises about 5 μg to about 100 μg of the purified RNA.

37. The method of claim 34 , wherein the pre-fusion stabilized spike protein comprises K417N, E484K, N501Y, and D614G amino acid substitutions relative to SEQ ID NO: 10.

38. The method of claim 36 , wherein the RNA is a mRNA.

39. A container comprising a vaccine dose comprising the pharmaceutical composition of claim 18 , wherein about 5 μg to about 100 μg of the RNA is present in said vaccine dose.

40. The container of claim 39 , wherein the pre-fusion stabilized spike protein comprises K417N, E484K, N501Y, and D614G amino acid substitutions relative to SEQ ID NO: 10.

41. The container of claim 39 , wherein the RNA is a mRNA.

42. The composition of claim 17 , wherein the SARS-COV-2 spike protein(S) comprises an amino acid sequence at least 94% identical to SEQ ID NO: 10.

43. The composition of claim 24 , wherein the SARS-COV-2 spike protein(S) comprises an amino acid sequence at least 94% identical to SEQ ID NO: 10.

44. The method of claim 38 , wherein the SARS-COV-2 spike protein(S) comprises an amino acid sequence at least 94% identical to SEQ ID NO: 10.

45. The container of claim 41 , wherein the SARS-COV-2 spike protein(S) comprises an amino acid sequence at least 94% identical to SEQ ID NO: 10.

46. The composition of claim 3 , wherein the SARS-COV-2 spike protein(S) comprises an amino acid sequence at least 94% identical to SEQ ID NO: 10.

47. The composition of claim 3 , wherein the pre-fusion stabilized spike protein comprises K417N, E484K, N501Y and D614G amino acid substitutions relative to SEQ ID NO: 10.

48. The composition of claim 3 , wherein the pre-fusion stabilized spike protein further comprises H69del and H70del amino acid deletions relative to SEQ ID NO: 10.

49. The composition of claim 3 , wherein the SARS-COV-2 spike protein further comprises a R403K amino acid substitution relative to SEQ ID NO: 10.

50. The composition of claim 47 , wherein the pre-fusion stabilized spike protein further comprises H69del and H70del amino acid deletions relative to SEQ ID NO: 10.

51. The method of claim 33 , wherein the pre-fusion stabilized spike protein further comprises H69del and H70del amino acid deletions relative to SEQ ID NO: 10.

52. The method of claim 33 , wherein the SARS-COV-2 spike protein further comprises a R403K amino acid substitution relative to SEQ ID NO: 10.

Assignments (2)
CHANGE OF NAME Recorded Mar 2, 2023
From: CUREVAC AG
To: CUREVAC SE
Reel/Frame 062931/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2022
From: RAUCH, SUSANNE; GROSSE, HANS WOLFGANG; PETSCH, BENJAMIN
To: CUREVAC AG
Reel/Frame 059624/0892 →
Continuity (5)
Provisional Application 63129395 · Dec 22, 2020
Provisional Application 63119390 · Nov 30, 2020
Provisional Application 63113159 · Nov 12, 2020
Provisional Application 63112106 · Nov 10, 2020
Related Publication 20240277830A1 · Aug 22, 2024
References Cited (400)
US 8691966B2 · Kariko et al. · 2014 [cited by applicant]
US 9364435B2 · Yaworski et al. · 2016 [cited by applicant]
US 9428535B2 · de Fougerolles et al. · 2016 [cited by applicant]
US 9476055B2 · Sahin et al. · 2016 [cited by applicant]
US 9504651B2 · Maclachlan et al. · 2016 [cited by applicant]
US 9518272B2 · Yaworski et al. · 2016 [cited by applicant]
US 9657295B2 · Schrum et al. · 2017 [cited by applicant]
US 9758795B2 · Cullis et al. · 2017 [cited by applicant]
US 9850269B2 · DeRosa et al. · 2017 [cited by applicant]
US 9868692B2 · Benenato · 2018 [cited by applicant]
US 9943612B2 · Scharenberg et al. · 2018 [cited by applicant]
US 10017543B2 · Kwong et al. · 2018 [cited by applicant]
US 10022435B2 · Ciaramella et al. · 2018 [cited by applicant]
US 10064959B2 · Schrum et al. · 2018 [cited by applicant]
US 10266485B2 · Benenato · 2019 [cited by applicant]
US 10442756B2 · Benenato et al. · 2019 [cited by applicant]
US 10577403B2 · De Fougerolles et al. · 2020 [cited by applicant]
US 10702600B1 · Ciaramella et al. · 2020 [cited by applicant]
US 10703789B2 · De Fougerolles et al. · 2020 [cited by applicant]
US 10772975B2 · Bancel et al. · 2020 [cited by applicant]
US 10898574B2 · de Fougerolles et al. · 2021 [cited by applicant]
US 10933127B2 · Ciaramella et al. · 2021 [cited by applicant]
US 10953089B1 · Smith et al. · 2021 [cited by applicant]
US 11060107B2 · Weissman et al. · 2021 [cited by applicant]
US 11078242B1 · Roy et al. · 2021 [cited by applicant]
US 11202793B2 · Hoge et al. · 2021 [cited by applicant]
US 11241493B2 · Rauch et al. · 2022 [cited by applicant]
US 11471525B2 · Rauch et al. · 2022 [cited by applicant]
US 11576966B2 · Rauch et al. · 2023 [cited by applicant]
US 11596686B2 · Rauch et al. · 2023 [cited by applicant]
US 11872280B2 · Roth et al. · 2024 [cited by applicant]
US 11918643B2 · Roth et al. · 2024 [cited by applicant]
US 20050032730A1 · von der Mülbe et al. · 2005 [cited by applicant]
US 20050059624A1 · Hoerr et al. · 2005 [cited by applicant]
US 20050250723A1 · Hoerr et al. · 2005 [cited by applicant]
US 20060188490A1 · Hoerr et al. · 2006 [cited by applicant]
US 20080025944A1 · Hoerr et al. · 2008 [cited by applicant]
US 20080267873A1 · Hoerr et al. · 2008 [cited by applicant]
US 20090324584A1 · Hoerr et al. · 2009 [cited by applicant]
US 20100048883A1 · Ketterer et al. · 2010 [cited by applicant]
US 20100189729A1 · Hoerr et al. · 2010 [cited by applicant]
US 20100203076A1 · Fotin-Mleczek et al. · 2010 [cited by applicant]
US 20100291156A1 · Barner et al. · 2010 [cited by applicant]
US 20100305196A1 · Probst et al. · 2010 [cited by applicant]
US 20110053829A1 · Baumhof et al. · 2011 [cited by applicant]
US 20110250225A1 · Fotin-Mleczek et al. · 2011 [cited by applicant]
US 20120021043A1 · Kramps et al. · 2012 [cited by applicant]
US 20120258046A1 · Mutzke · 2012 [cited by applicant]
US 20130129754A1 · Thess et al. · 2013 [cited by applicant]
US 20130142818A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130259879A1 · Baumhof et al. · 2013 [cited by applicant]
US 20130280283A1 · Lorenz et al. · 2013 [cited by applicant]
US 20130295043A1 · Kallen et al. · 2013 [cited by applicant]
US 20130336998A1 · Kallen et al. · 2013 [cited by applicant]
US 20150037326A1 · Butler-Ransohoff et al. · 2015 [cited by applicant]
US 20150050302A1 · Thess · 2015 [cited by applicant]
US 20150057340A1 · Thess et al. · 2015 [cited by applicant]
US 20150093413A1 · Thess et al. · 2015 [cited by applicant]
US 20150118183A1 · Baumhof · 2015 [cited by applicant]
US 20150118264A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150165006A1 · Thess et al. · 2015 [cited by applicant]
US 20150184195A1 · Thess · 2015 [cited by applicant]
US 20150218554A1 · Thess · 2015 [cited by applicant]
US 20150306249A1 · Baumhof et al. · 2015 [cited by applicant]
US 20150320847A1 · Thess et al. · 2015 [cited by applicant]
US 20160024139A1 · Berlanda Scorza et al. · 2016 [cited by applicant]
US 20160130345A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20160166668A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166678A1 · Kallen et al. · 2016 [cited by applicant]
US 20160166710A1 · Baumhof · 2016 [cited by applicant]
US 20160166711A1 · Schnee et al. · 2016 [cited by applicant]
US 20160168207A1 · Kramps et al. · 2016 [cited by applicant]
US 20160168227A1 · Kallen et al. · 2016 [cited by applicant]
US 20160235864A1 · Schlake et al. · 2016 [cited by applicant]
US 20160304883A1 · Grund et al. · 2016 [cited by applicant]
US 20160304938A1 · Wochner · 2016 [cited by applicant]
US 20160326575A1 · von der Mülbe · 2016 [cited by applicant]
US 20160331844A1 · Fotin-Mleczek et al. · 2016 [cited by applicant]
US 20170014496A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170029847A1 · Thess · 2017 [cited by applicant]
US 20170114378A1 · Wochner et al. · 2017 [cited by applicant]
US 20170252430A1 · Fotin-Mleczek et al. · 2017 [cited by applicant]
US 20170326225A1 · Rauch et al. · 2017 [cited by applicant]
US 20180044687A1 · Thess et al. · 2018 [cited by applicant]
US 20180125952A1 · Fotin-Mleczek et al. · 2018 [cited by applicant]
US 20180126003A1 · Hoerr · 2018 [cited by applicant]
US 20180142275A1 · Roos et al. · 2018 [cited by applicant]
US 20180147146A1 · Eber et al. · 2018 [cited by applicant]
US 20180148727A1 · Grund et al. · 2018 [cited by applicant]
US 20180201967A1 · Eber et al. · 2018 [cited by applicant]
US 20180208957A1 · Roos et al. · 2018 [cited by applicant]
US 20180214537A1 · Mutzke et al. · 2018 [cited by applicant]
US 20180237786A1 · Schlake et al. · 2018 [cited by applicant]
US 20180237817A1 · Roos et al. · 2018 [cited by applicant]
US 20180243219A1 · Ketterer et al. · 2018 [cited by applicant]
US 20180296663A1 · Hipp et al. · 2018 [cited by applicant]
US 20180298372A1 · Funkner et al. · 2018 [cited by applicant]
US 20180303925A1 · Weissman et al. · 2018 [cited by applicant]
US 20180312545A1 · Baumhof et al. · 2018 [cited by applicant]
US 20180371392A1 · Mayer et al. · 2018 [cited by applicant]
US 20190010485A1 · Yazdan Panah et al. · 2019 [cited by applicant]
US 20190017100A1 · Wochner et al. · 2019 [cited by applicant]
US 20190024096A1 · Schmid et al. · 2019 [cited by applicant]
US 20190040378A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190049414A1 · Wochner et al. · 2019 [cited by applicant]
US 20190083602A1 · Roos et al. · 2019 [cited by applicant]
US 20190100784A1 · Eber et al. · 2019 [cited by applicant]
US 20190125857A1 · Rauch et al. · 2019 [cited by applicant]
US 20190133950A1 · Eber et al. · 2019 [cited by applicant]
US 20190160164A1 · Rauch et al. · 2019 [cited by applicant]
US 20190177714A1 · Kunze et al. · 2019 [cited by applicant]
US 20190185859A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190194760A1 · Koch et al. · 2019 [cited by applicant]
US 20190225971A1 · Williams · 2019 [cited by applicant]
US 20190241633A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190249219A1 · Reichert et al. · 2019 [cited by applicant]
US 20190336608A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190336611A1 · Baumhof et al. · 2019 [cited by applicant]
US 20190343933A1 · Horscroft et al. · 2019 [cited by applicant]
US 20190343942A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20190351044A1 · Jasny et al. · 2019 [cited by applicant]
US 20190351047A1 · Jasny et al. · 2019 [cited by applicant]
US 20190351048A1 · Rauch · 2019 [cited by applicant]
US 20190381180A1 · Baumhof et al. · 2019 [cited by applicant]
US 20200023076A1 · Fotin-Mleczek et al. · 2020 [cited by applicant]
US 20200030432A1 · Ciaramella et al. · 2020 [cited by applicant]
US 20200061185A1 · Graham et al. · 2020 [cited by applicant]
US 20200085852A1 · Fotin-Mleczek · 2020 [cited by applicant]
US 20200085944A1 · Heidenreich et al. · 2020 [cited by applicant]
US 20200149026A1 · Horscroft et al. · 2020 [cited by applicant]
US 20200163878A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200179526A1 · Baumhof et al. · 2020 [cited by applicant]
US 20200197510A1 · Ciaramella et al. · 2020 [cited by applicant]
US 20200282046A1 · Ciaramella et al. · 2020 [cited by applicant]
US 20200318097A1 · Funkner et al. · 2020 [cited by applicant]
US 20200392572A1 · Yazdan Panah et al. · 2020 [cited by applicant]
US 20210023199A1 · Kallen et al. · 2021 [cited by applicant]
US 20210030864A1 · Petsch et al. · 2021 [cited by applicant]
US 20210030866A1 · Kallen et al. · 2021 [cited by applicant]
US 20210060175A1 · Fotin-Mleczek et al. · 2021 [cited by applicant]
US 20210069315A1 · Baumhof et al. · 2021 [cited by applicant]
US 20210162037A1 · Jasny et al. · 2021 [cited by applicant]
US 20210170017A1 · Lutz et al. · 2021 [cited by applicant]
US 20210180106A1 · Wochner et al. · 2021 [cited by applicant]
US 20210205434A1 · Petsch et al. · 2021 [cited by applicant]
US 20210222178A1 · Linke et al. · 2021 [cited by applicant]
US 20210228707A1 · Metkar et al. · 2021 [cited by applicant]
US 20210228708A1 · Smith et al. · 2021 [cited by applicant]
US 20210228709A1 · Smith et al. · 2021 [cited by applicant]
US 20210246170A1 · Langedijk et al. · 2021 [cited by applicant]
US 20210253645A1 · Gershoni et al. · 2021 [cited by applicant]
US 20210260178A1 · Jasny et al. · 2021 [cited by applicant]
US 20210261897A1 · Yazdan Panah et al. · 2021 [cited by applicant]
US 20210361761A1 · Lutz et al. · 2021 [cited by applicant]
US 20210379181A1 · Rauch et al. · 2021 [cited by applicant]
US 20210403925A1 · Chevessier-Tünnesen et al. · 2021 [cited by applicant]
US 20220040281A1 · Schwendt et al. · 2022 [cited by applicant]
US 20220073962A1 · Schwenger et al. · 2022 [cited by applicant]
US 20220133908A1 · Rejman et al. · 2022 [cited by applicant]
US 20220144877A1 · Heinz et al. · 2022 [cited by applicant]
US 20220202930A1 · Roth et al. · 2022 [cited by applicant]
US 20220347289A1 · Chen et al. · 2022 [cited by applicant]
US 20240156946A1 · Roth et al. · 2024 [cited by applicant]
US 20240207389A1 · Penaloza-Macmaster · 2024 [cited by applicant]
CN 111228475 · 2020 [cited by applicant]
CN 111606980 · 2020 [cited by applicant]
CN 111606981 · 2020 [cited by applicant]
CN 111647053 · 2020 [cited by applicant]
CN 111732638 · 2020 [cited by applicant]
CN 111778264 · 2020 [cited by applicant]
CN 111821433 · 2020 [cited by applicant]
CN 111333704B · 2021 [cited by applicant]
CN 112226445 · 2021 [cited by applicant]
CN 112266411 · 2021 [cited by applicant]
CN 111518175B · 2021 [cited by applicant]
CN 112300251 · 2021 [cited by applicant]
CN 112390863 · 2021 [cited by applicant]
EP 2791160B1 · 2014 [cited by applicant]
EP 3035959 · 2016 [cited by applicant]
EP 3336082 · 2020 [cited by applicant]
WO WO2006068663 · 2006 [cited by applicant]
WO WO2006078294 · 2006 [cited by applicant]
WO WO2007024708 · 2007 [cited by applicant]
WO WO2007024941 · 2007 [cited by applicant]
WO WO2008016473 · 2008 [cited by applicant]
WO WO2008157688 · 2008 [cited by applicant]
WO WO2008077592 · 2008 [cited by applicant]
WO WO2009030481 · 2009 [cited by applicant]
WO WO2009149253 · 2009 [cited by applicant]
WO WO2011005799 · 2011 [cited by applicant]
WO WO2011015347 · 2011 [cited by applicant]
WO WO2011068810 · 2011 [cited by applicant]
WO WO2011071931 · 2011 [cited by applicant]
WO WO2011076807 · 2011 [cited by applicant]
WO WO2012006369 · 2012 [cited by applicant]
WO WO2012006372 · 2012 [cited by applicant]
WO WO2012006377 · 2012 [cited by applicant]
WO WO2012006378 · 2012 [cited by applicant]
WO WO2012030901 · 2012 [cited by applicant]
WO WO2012031043 · 2012 [cited by applicant]
WO WO2012031046 · 2012 [cited by applicant]
WO WO2012116810 · 2012 [cited by applicant]
WO WO2012116811 · 2012 [cited by applicant]
WO WO2013006825 · 2013 [cited by applicant]
WO WO2013033563 · 2013 [cited by applicant]
WO WO2013059475 · 2013 [cited by applicant]
WO WO2013151736 · 2013 [cited by applicant]
WO WO2014152966 · 2014 [cited by applicant]
WO WO2014152027 · 2014 [cited by applicant]
WO WO2015164674 · 2015 [cited by applicant]
WO WO2015164773 · 2015 [cited by applicant]
WO WO2015199952 · 2015 [cited by applicant]
WO WO2016022914 · 2016 [cited by applicant]
WO WO2016165831 · 2016 [cited by applicant]
WO WO2016176330 · 2016 [cited by applicant]
WO WO2016193206 · 2016 [cited by applicant]
WO WO2017004143 · 2017 [cited by applicant]
WO WO2017053297 · 2017 [cited by applicant]
WO WO2017066781 · 2017 [cited by applicant]
WO WO2017066782 · 2017 [cited by applicant]
WO WO2017066789 · 2017 [cited by applicant]
WO WO2017066791 · 2017 [cited by applicant]
WO WO2017066793 · 2017 [cited by applicant]
WO WO2017066797 · 2017 [cited by applicant]
WO WO2017070626 · 2017 [cited by applicant]
WO WO2017137095 · 2017 [cited by applicant]
WO WO2017140905 · 2017 [cited by applicant]
WO WO2018075827 · 2018 [cited by applicant]
WO WO2017075531 · 2018 [cited by applicant]
WO WO2018078053 · 2018 [cited by applicant]
WO WO2018081318 · 2018 [cited by applicant]
WO WO2018081480 · 2018 [cited by applicant]
WO WO2018170347 · 2018 [cited by applicant]
WO WO2018172556 · 2018 [cited by applicant]
WO WO2018211038 · 2018 [cited by applicant]
WO WO2019077001 · 2019 [cited by applicant]
WO WO2019092153 · 2019 [cited by applicant]
WO WO2019193183 · 2019 [cited by applicant]
WO WO2019222424 · 2019 [cited by applicant]
WO WO2019226925 · 2019 [cited by applicant]
WO WO2019232095 · 2019 [cited by applicant]
WO WO2019232097 · 2019 [cited by applicant]
WO WO2019232208 · 2019 [cited by applicant]
WO WO2020002525 · 2020 [cited by applicant]
WO WO2020002598 · 2020 [cited by applicant]
WO WO2020123300 · 2020 [cited by applicant]
WO WO2020127959 · 2020 [cited by applicant]
WO WO2020128031 · 2020 [cited by applicant]
WO WO2020254535 · 2020 [cited by applicant]
WO WO2021028439 · 2021 [cited by applicant]
WO WO2021030701 · 2021 [cited by applicant]
WO WO2021123332 · 2021 [cited by applicant]
WO WO2021147025 · 2021 [cited by applicant]
WO WO2021151099 · 2021 [cited by applicant]
WO WO2021154763 · 2021 [cited by applicant]
WO WO2021154828 · 2021 [cited by applicant]
WO WO2021155323 · 2021 [cited by applicant]
WO WO2021155760 · 2021 [cited by applicant]
WO WO2021156267 · 2021 [cited by applicant]
WO WO2021159040 · 2021 [cited by applicant]
WO WO2021159985 · 2021 [cited by applicant]
WO WO2021160036 · 2021 [cited by applicant]
WO WO2021160346 · 2021 [cited by applicant]
WO WO2021160850 · 2021 [cited by applicant]
WO WO2021160881 · 2021 [cited by applicant]
WO WO2021161043 · 2021 [cited by applicant]
WO WO2021163222 · 2021 [cited by applicant]
WO WO2021163365 · 2021 [cited by applicant]
WO WO2021163371 · 2021 [cited by applicant]
WO WO2021163398 · 2021 [cited by applicant]
WO WO2021163427 · 2021 [cited by applicant]
WO WO2021163438 · 2021 [cited by applicant]
WO WO2021163456 · 2021 [cited by applicant]
WO WO2021163536 · 2021 [cited by applicant]
WO WO2021163584 · 2021 [cited by applicant]
WO WO2021163622 · 2021 [cited by applicant]
WO WO2021202734 · 2021 [cited by applicant]
WO WO2021209970 · 2021 [cited by applicant]
WO WO2021213924 · 2021 [cited by applicant]
WO WO2021213945 · 2021 [cited by applicant]
WO WO2021214204 · 2021 [cited by applicant]
WO WO2021222304 · 2021 [cited by applicant]
WO WO2021228842 · 2021 [cited by applicant]
WO WO2021236854 · 2021 [cited by applicant]
WO WO2021239880 · 2021 [cited by applicant]
WO WO2021243122 · 2021 [cited by applicant]
WO WO2021245611 · 2021 [cited by applicant]
WO WO2022067010 · 2022 [cited by applicant]
WO WO2022110099 · 2022 [cited by applicant]
WO WO2022155524 · 2022 [cited by applicant]
WO WO2022155530 · 2022 [cited by applicant]
WO WO2022180219 · 2022 [cited by applicant]
WO WO2023051701 · 2023 [cited by applicant]
WO WO2023064907 · 2023 [cited by applicant]
WO WO2023086961 · 2023 [cited by applicant]
Lee et al., “Human neutralzising antibodies elicited by SARS-CoV-2 non-D614G variants offer cross-protection against the SARS-CoV-2 D614G variant,” Clinical & Translational Immunology, 10:e1241, pp. 1-10, 2021. [cited by applicant]
Toyoshima et al., “SARS-CoV-2 genomic variations associated with mortality rate of COVID-19,” Journal of Human Genetics, 65:1075-1082, 2020. [cited by applicant]
Acuitas Therapeutics Inc.'s Memorandum in Support of Combined Motion to Intervene, Sever, and Stay in [cited by applicant]
Complaint for Declaratory Judgment of Inventorship in [cited by applicant]
Office Communication issued in U.S. Appl. No. 18/179,352, mailed Jul. 6, 2023. [cited by applicant]
U.S. Appl. No. 62/967,006, entitled “Coronavirus RNA vaccines,” filed Jan. 28, 2020. [cited by applicant]
U.S. Appl. No. 17/829,004, filed Jun. 1, 2022, Roth et al. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/546,414, mailed May 9, 2022. [cited by applicant]
Wrapp et al., “Cryo-EM stmcture of the 2019-nCoV spike in the prefusion conformation,” Science, 367:1260-1263, 2020. [cited by applicant]
Armbruster et al., “Advances in RNA vaccines for preventive indications: A case study of a vaccine against Rabies,” Vaccines 7:132, pp. 1-12, 2019. [cited by applicant]
Chan et al., “Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan,” Emerging Microbes & Infections 9:221-236, 2020. [cited by applicant]
Pascolo, “Messenger RNA-based vaccines,” Expert Opinion on Biological Therapy, 4:1285-1294, 2004. [cited by applicant]
“CureVac Final Data from Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV, Demonstrates Protection in Age Group of 18 to 60”, press release, Jun. 30, 2021. [cited by applicant]
“CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV”, press release, Jun. 16, 2021. [cited by applicant]
“CureVac: Final Analysis of Pivotal Phase 2b/3 HERALD Study”, presentation, Jul. 1, 2021. [cited by applicant]
“CureVac: Second Interim Analysis of Pivotal Phase 2b/3 HERALD Study”, presentation, Jun. 17, 2021. [cited by applicant]
“Final Analysis of Phase 2b/3 Clinical Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV”, transcript of conference call, Jul. 1, 2021. [cited by applicant]
“Results of Second Interim Analysis of CureVac's Pivotal Phase 2b/3 HERALD Study”, transcript of conference call, Jun. 17, 2021. [cited by applicant]
Battles et al., “Structure and immunogenicity of pre-fusion-stabilized human metapneumovirus F glycoprotein,” Nat Commun, 8(1):1528, 2017. [cited by applicant]
Hastie et al., “Structural basis for antibody-mediated neutralization of Lassa virus,” Science, 356(6341):923-928, 2017. [cited by applicant]
Holtkamp et al., “Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells,” Blood, 108(13):4009-4017, 2006. [cited by applicant]
Krarup et al., “A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism,” Nat Commun, 6:8143, 2015. [cited by applicant]
Orlandini von Niessen et al., “Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening,” Mol Ther, 27(4):824-836, 2019. [cited by applicant]
Rota et al., “Characterization of a novel coronavirus associated with severe acute respiratory syndrome,” Science, 300(5624):1394-1399, 2003. [cited by applicant]
Sanders & Moore, “Virus vaccines: proteins prefer prolines,” Cell Host Microbe, 29(3):327-333, 2021. [cited by applicant]
Sanders et al., “A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies,” PLoS Pathog, 9(9):e1003618, 2013. [cited by applicant]
Zaki et al., “Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia,” N Engl J Med, 367(19):1814-1820, 2012. [cited by applicant]
Phan, “Genetic diversity and evolution of SARS-CoV-2,” Infection, Genetics and Evolution 81:104260, pp. 1-3, 2020. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/546,414, mailed Apr. 20, 2022. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/526,912, mailed Jun. 20, 2022. [cited by applicant]
Gorbalenya et al., “The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2,” Nat. Microbiology, 5:536-544, 2020. [cited by applicant]
Kusters et al., “Manufacturing vaccines for an emerging viral infection—specific issues associated with the development of a prototype SARS vaccine,” Vaccine for Biodefense and Emerging and Neglected Diseases, 147-156, … [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/067,614, mailed Oct. 18, 2021. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/067,614, mailed Apr. 1, 2021. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/067,614, mailed Dec. 10, 2020. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/067,709, mailed Oct. 18, 2021. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/067,709, mailed Jul. 14, 2021. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/067,709, mailed Mar. 10, 2021. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/067,709, mailed Nov. 27, 2020. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/090,885, mailed Jun. 1, 2021. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/090,885, mailed Feb. 18, 2021. [cited by applicant]
Office Communication issued in U.S. Appl. No. 17/231,261, mailed Dec. 22, 2021. [cited by applicant]
Perlman et al., “Immunopathogenesis of coronavirus infections: Implications for SARS,” Nature Reviews Immunology, 5:917-927, 2005. [cited by applicant]
GISAID Sequence EPI_ISL_406862, Jan. 31, 2020. [cited by applicant]
Lutz et al., “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines,” npj Vaccines 2:29 (2017). [cited by applicant]
Penn Medicine webpage of YouTube video of Dr. Pardi, “Nucleoside-modified mRNA Vaccines Against SARS-CoV-2,” COVID-19 Symposium, Apr. 8, 2020. [cited by applicant]
Priority Document No. PCT/EP2020/061239, entitled “Coronavirus Vaccine,” filed Apr. 22, 2020. [cited by applicant]
Wölfel et al., “Virological assessment of hospitalized patients with COVID-2019,” Nature 581:465-469, 2020. [cited by applicant]
World Health Organization, “COVID-19—United Kingdom of Great Britain and Northern Ireland,” Disease Outbreak News, Dec. 21, 2020. [cited by applicant]
“CureVac Announces Positive Results in Low Dose—1 μg—Rabies Vaccine Clinical Phase 1 Study”, press release, Jan. 7, 2020. [cited by applicant]
Chen et al., “COVID-19 CG: Tracking SARS-CoV-2 mutations by locations and dates of interest,” bioRxiv 2020.09.23.310565, 2020. [cited by applicant]
Chen et al., “Mutations Strengthened SARS-CoV-2 Infectivity,” J Mol Bio 432:5212-5226, 2020. [cited by applicant]
Choi et al., “Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host,” N Engl J Med 383:2291-2293, 2020. [cited by applicant]
Escriou et al., “Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein,” Virology 452-453:32-41, 2014. [cited by applicant]
GenBank Accession No. MN908947.3, “Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome,” Mar. 18, 2020. [cited by applicant]
Kemp et al., “Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation,” medRxiv 2020.12.05.20241927, 2020. [cited by applicant]
Kemp et al., “Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70,” bioRxiv 2020.12.14.422555, 2020. [cited by applicant]
Korber et al., “Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2,” bioRxiv 2020.04.29.069054, 2020. [cited by applicant]
McCarthy et al., “Natural deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape,” bioRxiv 2020.11.19.389916, 2020. [cited by applicant]
McCarthy et al., “Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape,” Science 371:1139-1142, 2021. [cited by applicant]
Rambaut et al., “Preliminary genomic characterization of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations,” Virological.org (2020). [cited by applicant]
Stefanelli et al., “Whole genome and phylogenetic analysis of two SARS-CoV-2 strains isolated in Italy in January and Feb. 2020: additional clues on multiple introductions and further circulation in Europe,” Euro Survei… [cited by applicant]
Zehender et al., “Genomic Characterisation and Phylogenetic Analysis of Sars-Cov-2 in Italy,” medRxiv 2020.03.15.20032870, 2020. [cited by applicant]
“Comirnaty, Common name: COVID-19 mRNA vaccine (nucleoside-modified),” Assessment Report, European Medicines Agency, Dec. 21, 2020. [cited by applicant]
“COVID-19 vaccine moderna, Common name: COVID-19 mRNA Vaccine (nucleoside-modified),” Assessment Report, European Medicines Agency, Jan. 6, 2021. [cited by applicant]
Anderson et al., “Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults,” [cited by applicant]
Baden et al., “Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine,” [cited by applicant]
Corbett et al., “Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates,” [cited by applicant]
Corbett et al., “SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness,” bioRxiv preprint, Jun. 11, 2020. [cited by applicant]
GenBank Accession No. MN908947.1, “Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome,” Jan. 12, 2020. [cited by applicant]
Gerhardt et al., “A thermostable, flexible RNA vaccine delivery platform for pandemic response,” bioRxiv preprint, Feb. 2, 2021. [cited by applicant]
Hoffmann et al., “CVnCoV protects human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2,” bioRxiv preprint, Mar. 22, 2021. [cited by applicant]
Jackson et al., “An mRNA vaccine against SARS-CoV-2—preliminary report,” [cited by applicant]
Jiang et al., “SARS vaccine development,” [cited by applicant]
Kakodkar et al., “A comprehensive literature review on the clinical presentation, and management of the pandemic coronavirus disease 2019 (COVID-19),” [cited by applicant]
Muik et al., “Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera,” bioRxiv preprint, Jan. 19, 2021. [cited by applicant]
NCBI Accession No. NC_045512.1, “Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome,” Jan. 13, 2020. [cited by applicant]
Polack et al., “Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine,” [cited by applicant]
Rauch et al., “mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents,” bioRxiv preprint, Feb. 9, 2021. [cited by applicant]
Rauch et al., “mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection,” bioRxiv preprint, Dec. 23, 2020. [cited by applicant]
Rauch et al., “New vaccine technologies to combat outbreak situations,” [cited by applicant]
Sahin et al., “Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine,” medRxiv preprint, Jul. 20, 2020. [cited by applicant]
Schrörs et al., “Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates,” bioRxiv preprint, Mar. 15, 2021. [cited by applicant]
Vogel et al., “A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates,” bioRxiv preprint, Sep. 8, 2020. [cited by applicant]
Vogel et al., “BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2,” bioRxiv preprint, Dec. 11, 2020. [cited by applicant]
Wang et al., “An evidence based perspective on mRNA-SARS-CoV-2 vaccine development,” [cited by applicant]
Widge et al., “Durability of responses after SARS-CoV-2 mRNA-1273 vaccination,” [cited by applicant]
Database EMBL Accession No. MN908947, 2020. [cited by applicant]
Gebre et al., “Optimization of non-coding regions improves protective efficacy of an mRNA SARS-CoV-2 vaccine in nonhuman primates,” bioRxiv Preprint, Aug. 16, 2021. [cited by applicant]
Huang et al., “Clinical features of patients infection 2019 novel coronavims in Wuhan, China,” [cited by applicant]
PCT International Search Report and Written Opinion issued in International Application No. PCT/EP2021/052455 mailed Jun. 25, 2021. [cited by applicant]
Ball et al., “Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA,” Nano Lett. 18:3814-3822, 2018. [cited by applicant]
Becerra-Flores et al., “SARS-CoV-2 spike G614 mutation exhibits higher case fatality rate,” International Journal of Clinical Practice, 74:e13525, pp. 1-4, 2020. [cited by applicant]
Bhattacharya et al., “D614G mutation and SARS-CoV-2: impact on S-protein structure, function, infectivity, and immunity,” Applied Microbiology and Biotechnology, 105:9035-9045, 2021. [cited by applicant]
Bhattacharya et al., “Global spread of SARS-CoV-2 subtype with spike protein mutation D614G is shaped by human genomic variations that regulate expression on TMPRSSZ and MX1 gene,” bioRxiv, doi.org/10.1101/2020.05.04.07… [cited by applicant]
Burger et al., “Stabilizing Formulations for Inhalable Powders of Live-Attenuated Measles Virus Vaccine (abstract only),” J. Aerosol Medicine Pulmonary Delivery, 21: 2008. [cited by applicant]
Carnell et al., “SARS-CoV-2 spike protein arrested in the closed state induces potent neutralizing responses,” bioRxiv, doi.org/10.1101/2021.01.14.426695, pp. 1-27, 2021. [cited by applicant]
Carnell et al., “SARS-CoV-2 spike protein stabilized in the closed state induces potent neutralizing responses,” Journal of Virology 95:e00203-21, pp. 1-16, 2021. [cited by applicant]
Chang et al., “Synthesis and solution conformation studies of 3-substituted uridine and pseudouridine derivatives,” Bioorganic & Medicinal Chemistry, 16:2676-2686, 2008. Database EMBL Accession No. QIQ68534, Mar. 30, 20… [cited by applicant]
Database EMBL Accession No. QIQ68534, Mar. 30, 2020. [cited by applicant]
Du et al., “The spike protein of SARS-CoV—a target for vaccine and therapeutic development,” Nature Reviews Microbiology, 7:226-236, 2009. [cited by applicant]
Expert Opinion from Dr. G.T. Rijkers, dated Jul. 18, 2023, 18 pages. [cited by applicant]
Fechter et al., “Recognition of mRNA cap structures by viral and cellular proteins,” Journal of General Virology 86:1239-1249, 2005. [cited by applicant]
Follis et al., “Furin cleavage of the SARS coronavirus spike glycoprotein enhances cell- cell fusion but does not affect virion entry,” Virology 350:358-369, 2006. [cited by applicant]
Furuichi & Shatkin, “Viral and cellular mRNA capping: past and prospects,” Advances in Research 55:135-184, 2000. [cited by applicant]